Mechanism of action of phthalazinone derivatives against rabies virus
Antiviral Res. 2024 Feb 17:105838. doi: 10.1016/j.antiviral.2024.105838. Online ahead of print.ABSTRACTRabies, a viral zoonosis, is responsible for almost 59,000 deaths each year, despite the existence of an effective post-exposure prophylaxis. Indeed, rabies causes acute encephalomyelitis, with a case-fatality rate of 100 % after the onset of neurological clinical signs. Therefore, the development of therapies to inhibit the rabies virus (RABV) is crucial. Here, we identified, from a 30,000 compound library screening, phthalazinone derivative compounds as potent inhibitors of RABV infection and more broadly of Lyssavirus ...
Source: Antiviral Research - February 19, 2024 Category: Virology Authors: Victoire Perraud Bart Vanderhoydonck Guillaume Bouvier Guilherme Dias de Melo Amuri Kilonda Mohamed Koukni Dirk Jochmans Sophie Rog ée Youcef Ben Khalifa Lauriane Kergoat Julien Lannoy Tina Van Buyten Nadia Izadi-Pruneyre Patrick Chaltin Johan Neyts Arna Source Type: research
Molnupiravir inhibits human norovirus and rotavirus replication in 3D human intestinal enteroids
Antiviral Res. 2024 Feb 17:105839. doi: 10.1016/j.antiviral.2024.105839. Online ahead of print.ABSTRACTHuman norovirus (HuNoV) and human rotavirus (HRV) are the leading causes of gastrointestinal diarrhea. There are no approved antivirals and rotavirus vaccines are insufficient to cease HRV associated mortality. Furthermore, treatment of chronically infected immunocompromised patients is limited to off-label compassionate use of repurposed antivirals with limited efficacy, highlighting the urgent need of potent and specific antivirals for HuNoV and HRV. Recently, a major breakthrough in the in vitro cultivation of HuNoV an...
Source: Antiviral Research - February 19, 2024 Category: Virology Authors: Nanci Santos-Ferreira Jana Van Dycke Winston Chiu Johan Neyts Jelle Matthijnssens Joana Rocha-Pereira Source Type: research
Mechanism of action of phthalazinone derivatives against rabies virus
Antiviral Res. 2024 Feb 17:105838. doi: 10.1016/j.antiviral.2024.105838. Online ahead of print.ABSTRACTRabies, a viral zoonosis, is responsible for almost 59,000 deaths each year, despite the existence of an effective post-exposure prophylaxis. Indeed, rabies causes acute encephalomyelitis, with a case-fatality rate of 100 % after the onset of neurological clinical signs. Therefore, the development of therapies to inhibit the rabies virus (RABV) is crucial. Here, we identified, from a 30,000 compound library screening, phthalazinone derivative compounds as potent inhibitors of RABV infection and more broadly of Lyssavirus ...
Source: Antiviral Research - February 19, 2024 Category: Virology Authors: Victoire Perraud Bart Vanderhoydonck Guillaume Bouvier Guilherme Dias de Melo Amuri Kilonda Mohamed Koukni Dirk Jochmans Sophie Rog ée Youcef Ben Khalifa Lauriane Kergoat Julien Lannoy Tina Van Buyten Nadia Izadi-Pruneyre Patrick Chaltin Johan Neyts Arna Source Type: research
Neutralizing antibodies to block viral entry and for identification of entry inhibitors
Antiviral Res. 2024 Feb 16:105834. doi: 10.1016/j.antiviral.2024.105834. Online ahead of print.ABSTRACTNeutralizing antibodies (NAbs) are naturally produced by our immune system to combat viral infections. Clinically, neutralizing antibodies with potent efficacy and high specificity have been extensively used to prevent and treat a wide variety of viral infections, including Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Human Immunodeficiency Virus (HIV), Dengue Virus (DENV) and Hepatitis B Virus (HBV). An overwhelmingly large subset of clinically effective NAbs operates by targeting viral envelope proteins...
Source: Antiviral Research - February 18, 2024 Category: Virology Authors: Ee Hong Tam Yu Peng Megan Xin Yan Cheah Chuan Yan Tianshu Xiao Source Type: research
Neutralizing antibodies to block viral entry and for identification of entry inhibitors
Antiviral Res. 2024 Feb 16:105834. doi: 10.1016/j.antiviral.2024.105834. Online ahead of print.ABSTRACTNeutralizing antibodies (NAbs) are naturally produced by our immune system to combat viral infections. Clinically, neutralizing antibodies with potent efficacy and high specificity have been extensively used to prevent and treat a wide variety of viral infections, including Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Human Immunodeficiency Virus (HIV), Dengue Virus (DENV) and Hepatitis B Virus (HBV). An overwhelmingly large subset of clinically effective NAbs operates by targeting viral envelope proteins...
Source: Antiviral Research - February 18, 2024 Category: Virology Authors: Ee Hong Tam Yu Peng Megan Xin Yan Cheah Chuan Yan Tianshu Xiao Source Type: research
Porcine interferon- α linked to the porcine IgG-Fc induces prolonged and broad-spectrum antiviral effects against the foot-and-mouth disease virus
Antiviral Res. 2024 Feb 13:105836. doi: 10.1016/j.antiviral.2024.105836. Online ahead of print.ABSTRACTFoot-and-mouth disease (FMD) is an economically important disease, and the FMD virus (FMDV) can spread rapidly in susceptible animals. FMD is usually controlled through vaccination. However, commercial FMD vaccines are only effective 4-7 days after vaccination. Furthermore, FMDV comprises seven serotypes and various topotypes, and these aspects should be considered when selecting a vaccine. Antiviral agents could provide rapid and broad protection against FMDV. Therefore, this study aimed to develop a consensus porcine in...
Source: Antiviral Research - February 15, 2024 Category: Virology Authors: Gyeongmin Lee Aro Kim Hyo Rin Kang Ji-Hyeon Hwang Jong-Hyeon Park Min Ja Lee Byounghan Kim Su-Mi Kim Source Type: research
Porcine interferon- α linked to the porcine IgG-Fc induces prolonged and broad-spectrum antiviral effects against the foot-and-mouth disease virus
Antiviral Res. 2024 Feb 13:105836. doi: 10.1016/j.antiviral.2024.105836. Online ahead of print.ABSTRACTFoot-and-mouth disease (FMD) is an economically important disease, and the FMD virus (FMDV) can spread rapidly in susceptible animals. FMD is usually controlled through vaccination. However, commercial FMD vaccines are only effective 4-7 days after vaccination. Furthermore, FMDV comprises seven serotypes and various topotypes, and these aspects should be considered when selecting a vaccine. Antiviral agents could provide rapid and broad protection against FMDV. Therefore, this study aimed to develop a consensus porcine in...
Source: Antiviral Research - February 15, 2024 Category: Virology Authors: Gyeongmin Lee Aro Kim Hyo Rin Kang Ji-Hyeon Hwang Jong-Hyeon Park Min Ja Lee Byounghan Kim Su-Mi Kim Source Type: research
Porcine interferon- α linked to the porcine IgG-Fc induces prolonged and broad-spectrum antiviral effects against the foot-and-mouth disease virus
Antiviral Res. 2024 Feb 13:105836. doi: 10.1016/j.antiviral.2024.105836. Online ahead of print.ABSTRACTFoot-and-mouth disease (FMD) is an economically important disease, and the FMD virus (FMDV) can spread rapidly in susceptible animals. FMD is usually controlled through vaccination. However, commercial FMD vaccines are only effective 4-7 days after vaccination. Furthermore, FMDV comprises seven serotypes and various topotypes, and these aspects should be considered when selecting a vaccine. Antiviral agents could provide rapid and broad protection against FMDV. Therefore, this study aimed to develop a consensus porcine in...
Source: Antiviral Research - February 15, 2024 Category: Virology Authors: Gyeongmin Lee Aro Kim Hyo Rin Kang Ji-Hyeon Hwang Jong-Hyeon Park Min Ja Lee Byounghan Kim Su-Mi Kim Source Type: research
Discovery of cyperenoic acid as a potent and novel entry inhibitor of influenza A virus
Antiviral Res. 2024 Feb 11:105822. doi: 10.1016/j.antiviral.2024.105822. Online ahead of print.ABSTRACTInfluenza therapeutics with new targets and modes of action are urgently needed due to the frequent emergence of mutants resistant to currently available anti-influenza drugs. Here we report the in vitro and in vivo anti-influenza A virus activities of cyperenoic acid, a natural compound, which was isolated from a Chinese medicine Croton crassifolius Geise. Cyperenoic acid could potently suppress H1N1, H3N2 and H9N2 virus replication with IC50 values ranging from 0.12 to 15.13 μM, and showed a low cytotoxicity against MD...
Source: Antiviral Research - February 13, 2024 Category: Virology Authors: Xiaoli Zhang Yiping Xia Peibo Li Zhongnan Wu Ruilin Li Jialiao Cai Yubo Zhang Guocai Wang Yaolan Li Wei Tang Weiwei Su Source Type: research
Unmasking the potential of secretory IgA and its pivotal role in protection from respiratory viruses
Antiviral Res. 2024 Feb 6:105823. doi: 10.1016/j.antiviral.2024.105823. Online ahead of print.ABSTRACTMucosal immunity has regained its spotlight amidst the ongoing Coronavirus Disease 19 (COVID-19) pandemic, with numerous studies highlighting the crucial role of mucosal secretory IgA (SIgA) in protection against SARS-CoV-2 infections. The observed limitations in the efficacy of currently authorized COVID-19 vaccines in inducing effective mucosal immune responses remind us of the limitations of systemic vaccination in promoting protective mucosal immunity. This resurgence of interest has motivated the development of vaccin...
Source: Antiviral Research - February 8, 2024 Category: Virology Authors: Divya Sinha Melyssa Yaugel-Novoa Louis Waeckel St éphane Paul St éphanie Longet Source Type: research
Identification and assessment of the 1,6-dihydroxy-pyridin-2-one moiety as privileged scaffold for HBV ribonuclease H inhibition
Antiviral Res. 2024 Feb 5;223:105833. doi: 10.1016/j.antiviral.2024.105833. Online ahead of print.ABSTRACTThe Hepatitis B Virus (HBV) ribonuclease H (RNase H) although promising remains an unexploited therapeutic target. HBV RNase H inhibition causes premature termination of viral minus-polarity DNA strands, prevents the synthesis of the viral positive-polarity DNA strand, and causes accumulation of RNA:DNA heteroduplexes within viral capsids. As part of our ongoing research to develop more potent anti-HBV RNase H inhibitors, we designed, synthesized and analyzed a library of 18 novel compounds (17 N-hydroyxpyridinedione (...
Source: Antiviral Research - February 7, 2024 Category: Virology Authors: Erofili Giannakopoulou Vasiliki Pardali Tiffany C Edwards Molly Woodson Razia Tajwar John E Tavis Grigoris Zoidis Source Type: research
An adenovirus-vectored vaccine based on the N protein of feline coronavirus elicit robust protective immune responses
In this study, we developed a recombinant adenovirus vaccine, AD5-N, based on the nucleocapsid(N) protein of FCoV. The immunogenicity of AD5-N was evaluated through intramuscular immunization in 6-week-old Balb/c mice and 9-12 months old cats. Compared to the control group, AD5-N specifically induced a significant increase in IgG and SIgA levels in the vaccinated mice. Furthermore, AD5-N not only effectively promoted strong cellular immune responses in cats but also induced high levels of specific SIgA, effectively helping cats resist FCoV infection. Our findings suggest that adenovirus vector vaccines based on the N gene ...
Source: Antiviral Research - February 4, 2024 Category: Virology Authors: Yuanhong Wang Yun Liu Junna Wang Miao Zhang Xiaoying Deng Junhan Song Jie Zhu Lingxue Yu Guoxin Li Guangqing Liu Source Type: research
Miltefosine reduces coxsackievirus B3 lethality of mice with enhanced STAT3 activation
This study was therefore designated to test the antiviral effects of miltefosine against CVB3 in vitro and especially, in mice, as few studies test miltefosine in vitro, but not in vivo. In vitro results showed that miltefosine inhibited viral replication with enhanced activation of the cellular transcription factor, STAT3, which is reported to reduce CVB3 both in vitro and in mice. Notably, STAT3 knockdown abolished the anti-CVB3 activity of miltefosine in vitro. Mouse studies demonstrated that miltefosine pretreatment reduced CVB3 lethality of mice with decreased virus loads, organ damage, and apoptosis, but enhanced STA...
Source: Antiviral Research - February 3, 2024 Category: Virology Authors: Chun Yu Zhang Cheng-Huei Hung Yi-Ling Hsiao Tung-Miao Chang Yu-Chieh Su Li-Chiu Wang Shih-Min Wang Shun-Hua Chen Source Type: research
Therapeutic antibodies and alternative formats against SARS-CoV-2
Antiviral Res. 2024 Feb 1;223:105820. doi: 10.1016/j.antiviral.2024.105820. Online ahead of print.ABSTRACTThe COVID-19 pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) heavily burdened the entire world. Despite a prompt generation of vaccines and therapeutics to confront infection, the virus remains a threat. The ancestor viral strain has evolved into several variants of concern, with the Omicron variant now having many distinct sublineages. Consequently, most available antibodies targeting the spike went obsolete and thus new therapies or therapeutic formats are needed. In this review we foc...
Source: Antiviral Research - February 2, 2024 Category: Virology Authors: Rahel R Winiger Laurent Perez Source Type: research
Human neural progenitor cell models to study the antiviral effects and neuroprotective potential of approved and investigational human cytomegalovirus inhibitors
This study contributes to the understanding of the molecular mechanisms of cCMV neuropathogenesis and paves the way for further consideration of anti-HCMV drugs as candidate therapeutic agents for the amelioration of cCMV-associated neurological manifestations.PMID:38286212 | DOI:10.1016/j.antiviral.2024.105816 (Source: Antiviral Research)
Source: Antiviral Research - January 29, 2024 Category: Virology Authors: Marta Trevisan Anna Pianezzola Marco Onorati Lorenzo Apolloni Mauro Pistello Ravit Arav-Boger Giorgio Pal ù Beatrice Mercorelli Arianna Loregian Source Type: research
